Tesaro, Inc. clinical trials

Acquired by GlaxoSmithKline, Jan 22, 2019 · source ↗

The registry lists 33 studies whose lead sponsor is Tesaro, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 25, 2026.

Studies

Recruiting first, then most recently updated. Showing 33 of 33. All GlaxoSmithKline studies →

• Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingNCT02715284Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT02655016Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerActive, not recruitingNCT03602859Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)TerminatedNCT06964165Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted after Tesaro, Inc. became part of GlaxoSmithKline

• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingNCT03981796Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted after Tesaro, Inc. became part of GlaxoSmithKline

• A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyCompletedNCT03326193Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian CancerCompletedNCT03574779Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerCompletedNCT03329937Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib CapsuleCompletedNCT03329001Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedNCT03250832Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsCompletedNCT03308942Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedNCT01847274Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted after Tesaro, Inc. became part of GlaxoSmithKline

• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsTerminatedNCT01905592Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensCompletedNCT02354586Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedNCT03955471Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted after Tesaro, Inc. became part of GlaxoSmithKline

• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsCompletedNCT03359850Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With CancerCompletedNCT02476552Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT02048488Phase 1/2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian CancerApproved for marketingNCT03025867

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)WithdrawnNCT01244009Phase 2

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)TerminatedNCT01227941Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedNCT01499849Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)TerminatedNCT01110603Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyCompletedNCT01500226Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedNCT01500213Phase 3

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy VolunteersCompletedNCT02382666Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy SubjectsCompletedNCT02434861Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous RolapitantCompletedNCT02285647Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline

• A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)CompletedNCT00749502Phase 1

  Sponsor listed in the registry: Tesaro, Inc. · First submitted before Tesaro, Inc. became part of GlaxoSmithKline